Table 1.
Results of hepatitis B virus reactivation in patients with hepatocellular carcinoma receiving chemotherapy n (%)
| Ref. | No of patients | Chemotherapy | No of sessions | HBV reactivation (hepatitis)1 | Morbidity/mortality |
| Nagamatsu et al[29] | 33 | TAI | Weekly infusion | 24% | 3 died |
| Jang et al[27] | 146 | TACL | 5 (2-14) | 33.7% (21.7%) | 25 resolved, 3 died |
| Nagamatsu et al[10] | 17 | TAI | bi-weekly infusion | 67% | 3 died of HBV reactivation |
| Yeo et al[15] | 102 | Systemic chemotherapy | 3-weekly intervals | (36%) | Twelve died of HBV reactivation |
| Park et al[31] | 89 | TACE | 1 | 4.3% | 3 resolved, 1 had tumor-related hepatic failure |
| Jang et al[17] | 73 | TACL | 1-monthly intervals | 40.5% (29.7%) | One died of HBV reactivation |
| Kim et al[6] | 91 | TACE + RT | NA | 21.8% (a rebound of HBV DNA to > 100 × baseline) | 4 (12.5) developed CHB exacerbation |
| Lao et al[32] | 172 | TACE | 1.3/person | 14.5% | 12.1% in the reactivation group had CHB exacerbation |
| Jang et al[7] | 205 | LAT, TACL, TACL + RT | 1-2 monthly intervals | 30.2% | 10 developed decompensation, 1 died |
| Lao et al[30] | 320 | TACE | 4-10 weekly intervals | 17.5% | 26 (8.1) had liver functional deterioration |
1
The rates of hepatitis B virus (HBV) reactivation were the frequencies in antiviral-untreated patients. Modified from Jang et al[8]. HCC: Hepatocellular carcinoma; TAI: Transarterial infusion chemotherapy; TACL: Transarterial chemo-lipiodolization; TACE: Transarterial chemo-embolization; RT: Radiotherapy; LAT: Local ablation therapy.